Site menu

Search by ticker code:
Generic filters

Menu

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Volpara (ASX:VHT) share price rises on pleasing business update

The Volpara Health Technologies Ltd (ASX: VHT) share price has gone up after the ASX healthcare share revealed a solid business update.

Volpara’s software is used to “better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions.”

Cashflow, credit and Microsoft

Volpara told investors a little about its quarterly cashflow.

It said that since its revised strategy that was implemented in July 2022, with staffing changes completed in late August 2022, the business has “operated on an approximately free cash flow break-even basis” with the FY24 first quarter delivering “another strong quarter of cash inflows”.

The company revealed it had over NZ$12 million of cash on hand at the end of the FY24 first quarter and that there is “repeatable operating cash flow positivity in sight.”

Credit facility reduction

Last year the company obtained a NZ$10 million revolving credit facility. But, due to its growing cashflow, it has decided to reduce the facility as it’s no longer considered necessary. The facility will now be NZ$2.5 million.

It was paying a line fee of 1.5% per year for the available facility, so it’s going to save NZ$112,500 per year. It will evaluate the cash position over the next six months, with the possibility of reducing the facility further.

Microsoft

The global tech giant chose Volpara as the winner for the healthcare and life sciences partner of the year award, chosen from over 4,200 submitted nominations from more than 100 countries.

This award “recognises a partner organisation that excels at providing innovative healthcare and life sciences solutions based on Microsoft cloud technologies.”

Last year, Microsoft provided guidance on using Microsoft’s Azure machine learning platform to improve Volpara’s breast arterial calcifications (BAC) model and data progressing. The project marked the beginning of a new application anticipated to enter Volpara into a new area of care.

Management comments

The Volpara CEO and Managing Director Teri Thomas said:

We are double delighted about this announcement. From a financial perspective, Volpara’s strategy continues to play out ahead of guidance, giving us the confidence to reduce reliance on banking facilities while simultaneously reducing costs.

Final thoughts on the Volpara share price

I think Volpara is a great business and that its improving cashflow position shows it can continue to do well if it keeps growing revenue, which it is.

Earnings can significantly improve from here, in my eyes, because of all of the new risk-related services it can encourage its existing client base to use.

It’s one of the most promising businesses around in my opinion.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content